Edition:
United Kingdom

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

2.27USD
18 Jan 2018
Change (% chg)

-- (--)
Prev Close
$2.27
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,241,802
52-wk High
$7.15
52-wk Low
$1.68

Latest Key Developments (Source: Significant Developments)

CVI Investments reports a 7.9 pct passive stake in Synergy Pharmaceuticals as of Nov 13, 2017
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Synergy Pharmaceuticals Inc :CVI Investments Inc reports a 7.9 percent passive stake in Synergy Pharmaceuticals Inc as of November 13, 2017 - SEC Filing‍​.  Full Article

Synergy Pharma announces pricing of offering of common stock and warrants
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals announces pricing of offering of common stock and warrants.Synergy Pharmaceuticals - ‍pricing of offering of 21.7 million shares with accompanying warrants at combined price to public of $2.58/share and warrant​.  Full Article

Synergy Pharmaceuticals posts Q3 loss per share $0.22
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals reports third quarter 2017 financial results and business update.Q3 loss per share $0.22.Q3 sales $5.0 million versus I/B/E/S view $4.5 million.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Synergy Pharmaceuticals Inc - ‍cash and cash equivalents were about $117.8 million at end of quarter​.  Full Article

Synergy Pharma's bowel drug succeeds in first phase 3 trial
Friday, 9 Dec 2016 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals announces positive results in first phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C) . Synergy Pharmaceuticals Inc - preliminary analysis of data indicates that both plecanatide 3 mg and 6 mg doses met study's primary endpoint . Synergy Pharmaceuticals -pending approval in CIC indication, co plans to file new drug application supplement with clinical data for plecanatide in IBS-C in q1 2017 . Synergy Pharmaceuticals Inc - four patients in trial (0.4%) experienced serious adverse events . Synergy Pharma- common adverse event was diarrhea that was in 3.2% of patients in 3 mg,3.7% patients in 6 mg dose groups versus 1.3% placebo-treated patients .Synergy Pharmaceuticals announces positive results in first phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C).  Full Article

Synergy Pharma Q2 net loss $38.6 million
Monday, 8 Aug 2016 

Synergy Pharmaceuticals Inc : Synergy pharmaceuticals reports second quarter 2016 financial results and business update .Net loss in q2 of 2016 was $38.6 million, as compared to a net loss of $33.7 million incurred in q2 of 2015.  Full Article

Synergy Pharma updates on FDA review clinical development program
Friday, 15 Jul 2016 

Synergy Pharmaceuticals Inc : Provides update on ongoing FDA review Of Plecanatide CIC NDA and IBS-C clinical development program . Provides update on ongoing FDA review of Plecanatide CIC NDA and IBS-C clinical development program . Company has decided to continue patient enrollment for its two ongoing phase 3 clinical trials with Plecanatide in IBS-C .Intend to file Plecanatide NDA in IBS-Cin Q1 of 2017.  Full Article

Synergy Pharmaceuticals reports Q1 loss per share $0.51
Tuesday, 10 May 2016 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals reports first quarter 2016 financial results and business update . Q1 loss per share $0.51 .Q1 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.  Full Article

Synergy Pharmaceuticals Inc announces $89.8 million registered direct offering of common stock
Thursday, 5 May 2016 

Synergy Pharmaceuticals Inc:Entered into definitive agreements with certain institutional investors to sell 29,948,334 shares of common stock at a price of $3.00 per share.Offering is expected to close on or about May 6, 2016.Intends to use net proceeds to fund its commercialization activities for plecanatide, further clinical development of plecanatide and dolcanatide and for working capital and other general corporate purposes.  Full Article